Hematology, myeloproliferative neoplasms
Dysregulated signaling is a hallmark of myeloproliferative neoplasms (MPNs). By directly examining primary patient samples, patient-specific signaling profiles can be generated at the single-cell level utilizing phospo-specific flow cytometry. This approach facilitates the identification of pathways and targets amenable to therapeutic intervention. The ultimate goal is to develop more specific therapies for MPN Patients.
- 2002: PhD, cancer biology, Northwestern University, Chicago
- 2004: MD, Northwestern University
- 2004 - 2006: Resident, internal medicine, Stanford University, Stanford, Calif.
- 2006 - 2010: Fellow, hematology/oncology, Stanford University
- 2007: American Board of Internal Medicine, Internal Medicine
- 2010: American Board of Internal Medicine, Hematology
Disclaimer: This listing may not include all articles associated with this physician and may include publications related to other physicians with a similar name.